Severe Systemic Infections: Recommended Dose: 5 mg/kg for at least 14 days. It should be administered by IV infusion at a rate of 2.5 mg/kg/hr. An initial test dose of 1 mg should be infused IV >15 min.
Ampholip has been administered for as long as 11 months and cumulative doses have been as high as 56.6 g without significant toxicity.
Children and Elderly with Systemic Fungal Infections: Systemic fungal infections in children and elderly have been treated successfully with Ampholip at doses comparable to the recommended adult dose on a body weight basis.
Neutropenic Patients with Systemic Fungal Infections: Ampholip has been successfully used to treat systemic fungal infections in patients who are severely neutropenic as a consequence of hematological malignancy or the use of cytotoxic or immunosuppressive drugs.
Administration: Ampholip suspension is to be diluted for IV infusion only.
As for use with all amphotericin B products, facilities for cardiopulmonary resuscitation should be readily at hand when administering Ampholip, due to the possible occurrence of anaphylactoid reactions.
During administration of Ampholip, serum creatinine levels should be measured to monitor the renal toxicity. Dose adjustments should be made only after taking into account the overall clinical condition of the patient.